<DOC>
	<DOCNO>NCT01098149</DOCNO>
	<brief_summary>Diabetic nephropathy become common primary renal disease end stage renal disease patient . The prevalence diabetic patient dialysis reach even 30 % dialysis population ( USRDS ) incidence rate , country , 40 % . The 5 year survive time diabetic patient dialysis 20 % , compare hypertension glomerulonephritis complication , still remain bad . Diabetes often associate several comorbid factor hypertension , autonomic neuropathy , vasculopathy , metabolic disorder ( ketoacidosis , poor glycaemic control ) , electrolyte disorder . So , diabetic patient fragile , rather poor tolerance dialysis , lack achievement dry body weight inadequate dialysis . In order gain detail insight possible good tolerance dialysis , arise elimination acetate dialysate bath ( Acetate Free Biofiltration ) use automatic system control blood volume ( Blood Volume Control ) , investigator would like investigate cardiovascular stability frequency intradialytic symptom prospective , randomize , cross-over study .</brief_summary>
	<brief_title>Tolerance Hemodialysis Insulin-Requiring Diabetic Patients : BD vs AFB With Blood Volume Biofeedback</brief_title>
	<detailed_description>Acetate-Free-Biofiltration ( AFB ) prove technique suitable treat critical patient , elder diabetic , frequency reduction hypotensive episode symptoms treatment well control metabolic aspect ( metabolic acidosis ) . The Blood Volume Control ( BVC ) tool , allow improve cardiovascular tolerance treatment , especially hypotension-prone patient , appear promise correction arterial hypertension induce hydro-saline overload . The use BVC AFB test verify behaviour kinetics electrolyte ( particular bicarbonate ) get good result , term improvement treatment tolerance , critical patient However , therapy ( AFB+BVC ) yet evaluate dialysis tolerance improvement diabetic concern , relative contribution give factor achieve result . The study , 9 month long , aim verify treatment tolerance insulin require diabetic patient , use standard bicarbonate dialysis ( BD ) , Acetate Free Biofiltration ( AFB ) and/or Blood Volume Control ( BVC ) . The study divide three phase : first one , three month long , baseline standard bicarbonate dialysis , patient shift AFB BVC , three month , last three month long phase , randomization , aim identify relative contribution factor ( absence acetate bath BVC ) treatment tolerance improvement ( ) . The treatment tolerance evaluate consider frequency intradialytic hypotensive event .</detailed_description>
	<mesh_term>Hypotension</mesh_term>
	<criteria>End stage renal disease patient Patients affect diabetic nephropathy insulin therapy , , least , 6 month Patients renal replacement therapy haemodialysis three time week , , least , 6 month . Age 18 85 year Patients affect neoplasm and/or mental illness Patients residual diuresis &gt; 500 ml/die ; Patients single needle bicarbonate dialysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Haemodialysis treatment tolerance</keyword>
	<keyword>acetate free biofiltration</keyword>
	<keyword>frequency hypotensive event dialysis</keyword>
	<keyword>nurse intervention dialysis</keyword>
</DOC>